Muhammad Absar, Amer Mahmood, Tanveer Akhtar, Sulman Basit, Khushnooda Ramzan, Abid Jameel, Sibtain Afzal, Anhar Ullah, Kulsoom Qureshi, Nawaf Alanazi, Zafar Iqbal
Tyrosine Kinase Inhibitors (TKIs) have significantly improved the clinical outcome of BCR-ABL+ Chronic Phase-Chronic Myeloid Leukemia (CP-CML).
CML
progression
DNA repair genes
FANCD2
PARP inhibitors
combination therapy